What Happened

Artiva Biotherapeutics announced Tuesday that it is ending development of AlloNK, its lead allogeneic NK cell therapy, following a risk-benefit review. The decision came after two patient deaths in a Phase 2a basket autoimmune disease trial and longer-term follow-up data that failed to show sufficient clinical response durability.

The company is cutting 94% of its workforce, leaving fewer than 10 of its 115 employees. It also canned a planned Phase 3 pivotal trial and is exploring strategic options including a merger, business combination, sale or licensing of assets, or dissolution and liquidation.

Who Is Affected

The layoffs affect approximately 108 employees, based on the company's 115 employees as of June 30. Artiva expects to complete the workforce reduction in the first quarter of 2027.

The FDA, investigators, and a data safety monitoring board had paused enrollment and dosing after the first death was reported. The second death was deemed unrelated to AlloNK, but a cause has not yet been determined.

Market Impact

Artiva still holds ~$319.1 million in cash, cash equivalents, and investments as of September 30, making it a viable M&A or licensing counterparty despite the pipeline setback.

• M&A potential: The strategic review explicitly includes a merger or sale, creating near-term outreach opportunities for advisory and banking services.
• Asset value: AlloNK data showed deep B cell depletion and clinical activity, but durability was insufficient — a key point in licensing discussions.
• Workforce shift: ~108 experienced biotech professionals will be available in Q1 2027, relevant for recruiting and talent placement.

What to Watch

Watch for Artiva's next strategic announcement — whether it pursues a merger, asset sale, or dissolution. The timeline for the workforce reduction and any buyer interest in AlloNK or the company's cash position will shape follow-up outreach.

Also monitor how the FDA and data safety monitoring board's response to the patient deaths influences other cell therapy developers' regulatory planning, as that may create additional account activity in the autoimmune space.

Related coverage

• EyePoint to halve workforce, end pivotal wet AMD trials early after second Phase 3 fail
• GSK plans 1,200+ layoffs at Belgium sites as $2.5B restructure gains momentum
• GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data